By Chris Wack
Roivant Sciences said its subsidiary Kinevant Sciences' phase 2 study of Namilumab failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis.
The phase 2 study showed that Namilumab failed to meet the primary endpoint of proportion of subjects with a rescue event during the double-blind period. Rescue event was defined as clinically significant worsening of a subject's disease requiring treatment, failure to adhere to protocol, or premature discontinuation from the study associated with lack of benefit during the double-blind treatment period.
Pulmonary sarcoidosis is a lung disease characterized by the presence of clumps of immune cells that can cause breathlessness, fatigue and pain.
The study's secondary goals, including change in percent predicted forced vital capacity, corticosteroid tapering success, and change in the patient reported King's Sarcoidosis Questionnaire failed to show a treatment benefit consistent with the primary endpoint.
The safety profile of namilumab in the study was similar to previous studies.
Kinevant will be discontinuing further development of namilumab for the treatment of sarcoidosis, and it will publish the results to inform future sarcoidosis research.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 03, 2024 07:35 ET (12:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。